I do not have a threshold for dosing based on BMI. Flat dosing is now typically used for single agent immunotherapeutic agents such as durvalumab. We still do not know the optimal dosing, schedule, or duration of therapy defining the use of immunotherapy in general. There are reports that obesity is...

This is a provocative question for many reasons. From a biologic point of view, the effect on obesity and the host immune system are an area of active studies. Some retrospective/preclinical studies suggest worse outcomes for obese patients treated with anti-PD1 therapy (Boi et al., PMID 33427691) w...